Antibacterial Activity of Nanostructured Zinc Oxide Tetrapods

Int J Mol Sci. 2023 Feb 8;24(4):3444. doi: 10.3390/ijms24043444.

Abstract

Zinc oxide (ZnO) tetrapods as microparticles with nanostructured surfaces show peculiar physical properties and anti-infective activities. The aim of this study was to investigate the antibacterial and bactericidal properties of ZnO tetrapods in comparison to spherical, unstructured ZnO particles. Additionally, killing rates of either methylene blue-treated or untreated tetrapods and spherical ZnO particles for Gram-negative and Gram-positive bacteria species were determined. ZnO tetrapods showed considerable bactericidal activity against Staphylococcus aureus, and Klebsiella pneumoniae isolates, including multi-resistant strains, while Pseudomonas aeruginosa and Enterococcus faecalis remained unaffected. Almost complete elimination was reached after 24 h for Staphylococcus aureus at 0.5 mg/mL and Klebsiella pneumoniae at 0.25 mg/mL. Surface modifications of spherical ZnO particles by treatment with methylene blue even improved the antibacterial activity against Staphylococcus aureus. Nanostructured surfaces of ZnO particles provide active and modifiable interfaces for the contact with and killing of bacteria. The application of solid state chemistry, i.e., the direct matter-to-matter interaction between active agent and bacterium, in the form of ZnO tetrapods and non-soluble ZnO particles, can add an additional principle to the spectrum of antibacterial mechanisms, which is, in contrast to soluble antibiotics, depending on the direct local contact with the microorganisms on tissue or material surfaces.

Keywords: Klebsiella pneumoniae; Staphylococcus aureus; zinc oxide tetrapods.

MeSH terms

  • Anti-Bacterial Agents / chemistry
  • Anti-Infective Agents*
  • Bacteria
  • Humans
  • Klebsiella pneumoniae
  • Methylene Blue
  • Microbial Sensitivity Tests
  • Staphylococcal Infections*
  • Zinc Oxide* / chemistry

Substances

  • Zinc Oxide
  • Methylene Blue
  • Anti-Bacterial Agents
  • Anti-Infective Agents

Grants and funding

This project was supported in part by the Excellence Cluster Precision Medicine in Chronic Inflammation (PMI) and by the Medical and Technical Faculties of the Christian-Albrecht University of Kiel.